NBIX: SEC Form 10-Q filed by Neurocrine Biosciences Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for NBIX
Across the 26 sessions after earlier NBIX headlines, the stock closed higher 14 times and lower 11 times, with a median move of 1.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NBIX | SPY |
|---|---|---|---|
| Jul 31, 2026 | Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results | -10.1% | +0.7% |
| Jul 24, 2026 | Neurocrine Biosciences Announces Key Leadership Hiring, Promotions | +0.9% | +0.1% |
| Jul 22, 2026 | Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer | -3.6% | -0.1% |
| Jul 10, 2026 | Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results | -1.9% | +0.4% |
| Jul 2, 2026 | Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia | +3.9% | -0.1% |
| Jun 16, 2026 | Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Periodand 1 other headline that session | -1.9% | -0.6% |
Quantisnow market dataNASDAQ
NBIX
Neurocrine Biosciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1996
Get push alerts for NBIX
Full NBIX profile on Quantisnow Follow NBIX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time